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We applied for the ﬁrst time an innovative ligand-based NMR methodology (STI) to a medicinal-chemistry
project aimed at the development of inhibitors for the enzyme 1-deoxy-D-xylulose-5-phosphate synthase
(DXS). DXS is the ﬁrst enzyme of the 2C-methyl-D-erythritol-4-phosphate (MEP) pathway, present in most
bacteria (and not in humans) and responsible for the synthesis of the essential isoprenoid precursors. We
designed de novo a ﬁrst generation of fragments, using Deinococcus radiodurans DXS as a model
enzyme, targeting the thiamine diphosphate (TDP) pocket of DXS whilst also exploring the putative
substrate-binding pocket, where selectivity over other human TDP-dependent enzymes could be
gained. The STI methodology – suitable for weak binders – was essential to determine the binding
mode in solution of one of the fragments, circumventing the requirement for an X-ray co-crystal
structure, which is known to be particularly challenging for this speciﬁc enzyme and in general for weak
binders. Based on this ﬁnding, we carried out fragment growing and optimisation, which led to a three-
fold more potent fragment, about as potent as the well-established thiamine analogue deazathiamine.
The STI methodology proved therefore its strong potential as a tool to support medicinal-chemistry
projects in their early stages, especially when dealing with weak binders.Introduction
Fragment-based design (FBD) has emerged as a powerful tool
for the discovery and optimisation of drug-like compounds.1
Whereas the most common approach for the identication of
fragments as hits still remains the screening of fragment
libraries,2 de novo design of fragments is attracting more and
more attention,3 in particular for targets for which an initial
screen of a fragment library is impossible owing to the type of
assay used or insuﬃcient quantities of protein available. The
use of FBD is particularly attractive due to its potential to cover a
greater fraction of chemical space and to aﬀord fragments with
high ligand eﬃciencies (LEs, dened as LE ¼ DG/N where DG
corresponds to the Gibbs free energy of binding (kcal mol1)
and N is the number of non-hydrogen atoms) that should beof Groningen, Nijenborgh 7, NL-9747 AG
irsch@rug.nl
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is work.
hemistry 2014maintained during the optimisation stages.4 Despite these
advantages, several hurdles persist: the fragment hit identied
may not be amenable to follow-up synthesis, which is oen a
time-consuming and resource-intensive undertaking. Further-
more, the fragment-to-lead process consists in optimising (e.g.,
fragment growing, fragment linking) the initial fragment hit
towards a more potent lead-like compound.5 During this
process, the binding mode of the initial fragment must be
maintained, requiring ideally a co-crystal structure of the
(modied) fragment to be solved at every optimisation step.6
Unfortunately, for approximately 40% of pharmaceutically
relevant protein targets, crystal structures of suﬃcient quality
cannot be obtained and for those proteins, which are crystal-
lisable, this is oen a time- and resource-consuming process, as
reliable soakable crystallographic systems are not always avail-
able.7 Moreover, it can be very diﬃcult to co-crystallise frag-
ments obtained in the early stage of the fragment-to-lead
process because of their weak aﬃnity for the target, requiring
prohibitively high ligand concentrations.
NMR spectroscopy can be particularly helpful in these cases,8
as it is suited for a wide range of binding aﬃnities and can
outperform other methods such as screening assays, surface
plasmon resonance and uorescence anisotropy in terms of the
detection of weak binders.9 A major advantage of NMR spec-
troscopy with respect to co-crystal structures is that information
about the bindingmode in solution is obtained. In addition, theChem. Sci., 2014, 5, 3543–3551 | 3543












































View Article Onlinerigid nature of co-crystal structures can lead to misinterpreta-
tions of the interactions between the designed ligand and the
protein.10
Whereas protein-observed NMR experiments are limited to
small protein targets (Mw < 50 kDa), which can be labelled and
puried in large amounts,5b ligand-observed NMR experiments
require less, unlabelled protein and enable direct identication
of the ligands as long as their chemical shis in solution are
known.11
We recently developed and validated retrospectively an
innovative, fast and reliable ligand-based NMR methodology12
extending the INPHARMA methodology13 to decipher the
binding mode of a ligand in solution using a very low concen-
tration of unlabelled protein (e.g., 30 mM). The latter aspect
makes this technique available for all targets with a certain size
(Mw > 30 kDa), including less established ones for which protein
expression is oen the bottleneck. The method covers a wide
range of binding aﬃnities (Kd from 1.0 mM to 2.0 mM), typically
observed for weakly to moderately binding fragments.
A combination of three NMR techniques is applied to
elucidate the binding mode of a ligand or fragment: (i) Satu-
ration-Transfer Diﬀerence (STD) yields information on the
protein-buried and water-exposed parts of the ligand,14 (ii)
Transfer-NOE (trNOE) reveals the bound ligand conformation
and (iii) INPHARMA derives the relative binding mode of two
ligands interacting with the same binding site.13 The method-
ology is termed STI, referring to its three NMR parameters STD,
trNOE and INPHARMA and holds the potential to represent an
attractive alternative to protein crystallography in both FBD and
structure-based design (SBD) projects. An INPHARMA-based
identication of the binding site of fragment-like molecules forScheme 1 (a) First step of the MEP pathway catalysed by DXS to aﬀo
representative isoprenoids, namely camphor (3) lanosterol (4) and vitam
3544 | Chem. Sci., 2014, 5, 3543–3551glycogen phosphorylase has been reported recently, which
illustrates the potential of this method.15
In the present work, we apply the STI methodology for the rst
time to the de novo FBD of inhibitors of the enzyme 1-deoxy-D-
xylulose-5-phosphate synthase (DXS), illustrating its potential
when applied in the early stages of medicinal-chemistry projects.
DXS catalyses the rst and rate-limiting step of the 2C-methyl-
D-erythritol-4-phosphate (MEP) pathway (also known as non-
mevalonate pathway) for the biosynthesis of isopentenyl
diphosphate (IPP, 1) and dimethylallyl diphosphate (DMAPP,
2).16 IPP and DMAPP are the universal precursors of isoprenoids,
a large and important class of natural products (e.g., camphor (3)
lanosterol (4) and vitamin A (5), Scheme 1a) featuring very diverse
structures and essential biological functions.17 The rst step of
the MEP pathway catalysed by DXS consists in the thiamine-
diphosphate (TDP)-dependent decarboxylative condensation of
pyruvate (6) and D-glyceraldehyde 3-phosphate (7, GAP) to aﬀord
1-deoxy-D-xylulose-5-phosphate (8, Scheme 1a). Whereas patho-
gens such as Mycobacterium tuberculosis and Plasmodium falci-
parum, causative agents of tuberculosis andmalaria, respectively,
use the MEP pathway for the biosynthesis of 1 and 2, humans
exclusively utilise the alternative mevalonate pathway, making
the enzymes of the MEP pathway attractive drug targets for the
development of new drugs against tuberculosis and malaria.18
Due to the emergence of several multi- and extensively-drug-
resistant strains of M. tuberculosis and P. falciparum, there is a
growing need for the development of new anti-infective agents
with new mechanisms of action.19
The involvement of DXS both in microbial thiamine (vitamin-
B1) biosynthesis20 as well as in vitamin-B6 biosynthesis21 renders
it a particularly interesting target, with the benet of interferingrd the ﬁnal products of the MEP pathway, 1 and 2, leading to three
in A (5). (b) Known inhibitors of DXS.
This journal is © The Royal Society of Chemistry 2014












































View Article Onlinewith three crucial bacterial biosynthetic pathways at once. On the
one hand, the similarity between DXS and mammalian TDP-
dependent enzymes such as transketolase (TK)22 and pyruvate
dehydrogenase (PDH)23 could give rise to selectivity problems in
the development of inhibitors against DXS, especially when tar-
geting the TDP-binding pocket (Fig. S1,† 20% identity overall,
47% identity in the TDP-binding pocket between human TK and
M. tuberculosis DXS). On the other hand, DXS has distinctive
features compared to other TDP-dependent enzymes suggesting
that selective inhibition of DXS over other TDP-dependent
enzymes could be possible: the peculiar domain arrangement of
Deinococcus radiodurans DXS (RCSB Protein Data Bank (PDB)
code: 2O1X) where the TDP-binding site is located within the
same monomer24 and not at the dimer interface like in its
mammalian homologues,26 the particularly large active site27 and
its unique catalytic mechanism, which requires the formation of
a ternary complex with pyruvate and GAP28 (in contrast, all the
other TDP-dependent enzymes follow classical ping-pong
kinetics in which the binding of acceptor substrate is preceded by
the activation of pyruvate and release of CO2).29 Therefore, ideally,
a DXS-inhibitor should be designed so as to target both the TDP-
binding pocket to enhance the aﬃnity and the substrate-binding
pocket to aﬀord selectivity.
The two crystal structures of DXS in complex with TDP
deposited in the PDB24 are not of the pathogenic organisms,
making the development of inhibitors for this enzyme a chal-
lenge. As a result, very few inhibitors of DXS have been reported
in the literature (9–14, Scheme 1b)30 and for none of them the
bindingmode has been validated. Only phosphonates 12 and 13
have been shown to compete with the binding of pyruvate by
kinetic studies.30d,fResults and discussion
De novo design and biochemical evaluation of rst-generation
fragments
As a starting point for our FBD, we decided to target the TDP-
binding pocket rather than the ill-dened substrate-bindingFig. 1 (a) TDP in the TDP-binding pocket ofD. radioduransDXS (PDB cod
(aminopyrimidine pocket), B (thiazolium pocket) and C (diphosphate p
radiodurans DXS. (c) Modelled binding mode of fragment 16 in D. radiod
yellow. Mg2+ ion is shown as a purple sphere. Inhibitor 15 skeleton: C: y
shown as dashed lines. The units for the distances indicated and the colou
generated using the software PyMOL.25
This journal is © The Royal Society of Chemistry 2014pocket. Despite the low lipophilic character of the TDP pocket
with respect to the average for druggable pockets,32 it obtained a
rather high Dscore when analysed with the programme DogSi-
teScore.33 The fragments were designed so that they could be
further grown either towards the diphosphate pocket or ideally
towards the substrate-binding pocket, where selectivity could be
gained.
We used D. radiodurans DXS as a model enzyme for our
studies given the high degree of sequence identity between D.
radiodurans DXS and M. tuberculosis DXS (38% overall, 68% in
the TDP-binding pocket (Fig. S1†).24 As a rst step towards the
development of inhibitors for DXS, we focused on designing
TDP-competitive fragments and therefore rst analysed the
binding mode of TDP, which is deeply buried inside D. radio-
durans DXS. As highlighted in Fig. 1a, the aminopyrimidine
moiety of TDP is involved in three hydrogen bonds with the
protein (d(N3/HN–Ala125) ¼ 3.1 A˚, d(H2N/O]C–Gly123) ¼
2.9 A˚, d(N1/HO–C–Glu373) ¼ 2.7 A˚) and a p-stacking interac-
tion with the side chain of Phe398. The catalytically active part
of TDP, the thiazolium ring, is surface-exposed and only
involved in a few hydrophobic interactions (with Ile187, Ile371
and Val80), while the diphosphate moiety engages in numerous
polar interactions both with polar amino-acid side chains and
with the protein backbone. The catalytic Mg2+ ion is complexed
by both phosphate groups.
The binding of TDP with DXS is rather tight (D. radiodurans
DXS, Kd ¼ 0.114  0.01 mM; M. tuberculosis DXS, Kd ¼ 3.1  0.30
mM, Fig. S2†). Moreover, by comparing the inhibitory potency of
deazathiamine 17 (IC50 ¼ 430  68 mM) and its diphosphory-
lated form, deazathiamine diphosphate 18 (IC50 ¼ 0.034 
0.006 mM),34 it is evident that the diphosphate moiety accounts
for a good part of its binding energy. Being aware of the chal-
lenges in targeting very polar diphosphate-binding pockets, we
decided to occupy the more druggable aminopyrimidine and
thiazolium pockets.
Using the modelling soware MOLOC,35 we designed frag-
ment 15 de novo (Fig 1b, Table 1). Docking with the FlexX
docking module in the LeadIT suite further guided oure: 2O1X). The three subpockets are highlighted and labelled as pocket A
ocket), respectively. (b) Modelled binding mode of fragment 15 in D.
urans DXS. Colour code: protein skeleton: C: grey; O: red; N: blue; S:
ellow. Inhibitor 16 skeleton: C: pink. Hydrogen bonds below 3.3 A˚ are
r code aremaintained throughout, if not stated otherwise. Figures were
Chem. Sci., 2014, 5, 3543–3551 | 3545
Table 1 Experimental IC50, experimental or calculated Ki values and
ligand eﬃciencies (LEs) of two modelled fragments (15, 16) and dea-
zathiamine (17); LEs are derived from experimentally determined IC50




1810  480 448  129 0.33







18, R ¼ P2O63 0.034  0.006d 0.007  0.001 0.44
a IC50 and calculated Ki values were determined using a photometric
assay using the programme Dynat.31 Full details of the biochemical
assay conditions and the calculation of the Ki values are provided in
the ESI. b Values indicate the ligand eﬃciency (LE) calculated as DG/
N, where DG corresponds to the Gibbs free binding energy (kcal
mol1) calculated as DG ¼ RT ln K0/Ki, Ki being the calculated
inhibition constant, unless stated otherwise. N corresponds to the
number of non-hydrogen atoms of that specic molecule. c The Ki
value and mode of inhibition of 17 were determined experimentally.
LE was derived from the experimental Ki. Full details of the
biochemical-assay conditions are provided in the ESI. d 18 was
isolated and tested as its ammonium tosylate salt.












































View Article Onlinemodelling studies.36 The favourable p-stacking interaction with
Phe398 is maintained in the same way as for TDP, but the
pyridine ring of 15 is slightly displaced with respect to the
amino-pyrimidine ring of TDP leading to a more favourable
parallel-displaced p-stacking interaction. In the modelled pose,
the imidazole ring of 15 is accommodated in the thiazolium
pocket and is displaced with respect to the thiazolium ring of
TDP. As a result, the van-der-Waals interactions with Ile187 and
Ile371 – which help to keep the thiazolium ring in place in the
case of TDP – should be strengthened.
According to the modelling studies, the imidazolic N3 is
involved in a favourable hydrogen bond with the side chain of
Ser186 (d(N/HO–Ser186) ¼ 3.0 A˚). The 3-methoxy group of the
pyridine ring forms a hydrogen bond with the backbone N–H of
Ala125 (d(O/HN–Ala125 ¼ 2.8 A˚), mimicking the hydrogen
bond of the N3 of the aminopyrimidine ring of TDP. Not
surprisingly, the N1 of the pyridine ring of 15 is not involved in a
hydrogen bond with Glu373 anymore, due to the displacement
of the ring with respect to the aminopyrimidine ring of TDP. We
carried out the synthesis of 15 in four steps using an SN2 reac-
tion as a key step to link the two aromatic rings (Scheme S1†).
Biochemical evaluation of 15 using a coupled DXS-IspC (1-
deoxy-D-xylulose-5-phosphate reductoisomerase) photometric
assay showed an IC50¼ 1.8 0.5 mM against D. radioduransDXS3546 | Chem. Sci., 2014, 5, 3543–3551(experimentally derived LE ¼ 0.33 kcal mol1). The imidazolyl
ring is a suitable platform to address both the diphosphate-
binding pocket and the newly identied pocket lined by resi-
dues His304, His82, His51, Phe109 and His43. This pocket,
from now on referred to as “histidine-rich pocket”, is presum-
ably involved in substrate-binding.
Fragment 16 (Fig. 1c, Table 1) was designed de novo so as to
explore this pocket, presumably involved also in the substrate-
recognition process. According to the modelling studies, we
introduced a pyrazole moiety bearing a diol functionality to
hydrogen bond to Lys101 (d(OH/2HN–Lys101 ¼ 3.3 A˚), Asp430
(d(OH/O]C–Asp430 ¼ 2.8 A˚) and His434(d(OH/N–His434 ¼
2.8 A˚). Although the pyrazolyl ring is not directly interacting
with His51, it is believed to interfere with the catalytic role of
His51, supposedly in the substrate-recognition process.37 An
ethylene linker (torsional angle s(Npyrazole–C–C–Cimidazole):
168) connects the pyrazolyl ring to an imidazolyl ring
accommodated in the thiazolium pocket. In addition to the van-
der-Waals interactions with the side chains of Ile187 and Ile371,
the imidazolyl ring is involved in a favourable S-aromatic
interaction with the side-chain sulfur atom of Met349. The
linker itself is also involved in numerous lipophilic contacts
with the side chain of Ile187 and aromatic hydrogen atoms of
Phe398. The synthesis of 16 relied on a regioselective alkylation
of an appropriately protected imidazole followed by introduc-
tion of the pyrazole in an SN2 reaction (Scheme S2†).
Biochemical evaluation of 16 resulted in an IC50 of 762  199
mM, with an experimentally derived LE of 0.32 kcal mol1. Just
like for fragment 15, the imidazolyl ring constitutes an equally
versatile platform for further fragment growing and optimisa-
tion of 16. Based on the LEs, both 15 and 16 can be considered
suitable starting points for further optimisation.Determination of the binding mode in solution using the STI
methodology
Before starting fragment optimisation, we validated the binding
mode of the two fragment hits identied. To do so, we applied
the novel STI NMR methodology (Fig. S3†) for the rst designed
fragments given the lack of a reliable crystallographic protocol
and the opportunity to obtain information about the binding
mode of small molecules in solution. In the rst stage, we
conducted STD experiments with ligands 15 and 16 (Fig. S4 and
S5†). Both molecules showed STD enhancement in the presence
of DXS, indicating that they bind to DXS. As expected, we
observed no STD enhancement for the fragments in a buﬀer
solution without DXS. The same observation holds true for
trNOE peaks in a NOESY spectrum. For the third step of the
methodology (INPHARMA), we chose deazathiamine (17) as a
reference ligand for our studies (STD experiments shown in
Fig. S6†).34 17 is structurally related to TDP and docking studies
supported our assumption that it binds in the TDP-binding
pocket (Fig. S7†). Moreover, the experimental determination of
the Ki value for 17 (Ki¼ 151 34 mM) conrmed that its mode of
inhibition is competitive with respect to TDP, making it a
suitable ligand for the INPHARMA methodology (Fig. S8†).This journal is © The Royal Society of Chemistry 2014
Fig. 2 (a) NOESY spectrum of inhibitors 15 and 17 in the presence of
DXS clearly shows trNOE (black) and INPHARMA (green) peaks. Peak
assignment is indicated on the axes for 15 (black) and 17 (blue). (b)
Binding mode for 15 and 17 in the TDP-binding pocket of D. radio-
durans DXS validated by the STI methodology. Deazathiamine (17)
skeleton: C: purple. Inhibitor 15 skeleton: C: orange.












































View Article OnlineIn order to observe INPHARMA peaks in a spectrum, the
ligands must have an oﬀ-rate from the target, which is large
enough to ensure that several exchange events can take place
during the NOESY mixing time of several 100 ms. When both
molecules target the same binding pocket, magnetisation of the
protons of the rst molecule will be transferred to the protein
protons and back to the protons of the secondmolecule, when it
is bound. 17 is a suitable choice in our case, given its IC50 of 430
 68 mM against D. radiodurans DXS.
Whereas we recorded a NOESY spectrum of the ligand
combination 17 and 15 (Fig. S9 and S10†) and were able to
clearly observe INPHARMA peaks, we were unable to observe
INPHARMA peaks for ligand combinations 17 with 16 and 15
with 16. We used the docking module FlexX to dock 15 and 16
into the crystal structure of D. radiodurans DXS. We generated
30 docking poses for each ligand and clustered them with an
RMSD diﬀerence of 3 A˚ using GROMACS to yield a set of
representative and diverse binding modes. From every cluster,
we used the structure with the best DG according to the scoring
function HYDE in the LeadIT suite for the back-calculation of
NMR data (Fig. S11 and S12, Table S1†).38 We also docked 17 in
the TDP-binding site of D. radiodurans DXS and, as expected,
found the top-ranked poses to overlap with TDP, which we used
as a reference for the INPHARMA calculations (Fig. S7, Table
S1†). We back-calculated the NMR peak volumes of all three
data sets (STD, trNOE and INPHARMA) for every docked pose,
using the soware SpINPHARMA (http://www.inpharma.de)
and scored the correlation between back-calculated and exper-
imental data using the Pearson correlation coeﬃcient to yield
RSTD, RtrNOE and RINPHARMA. We then combined these to RSTI by
averaging and selected the structure pair with the highest score
as the most accurate binding mode. The RSTI values for every
docked pose of each inhibitor are reported in Table S1.† For 17,
we identied three diﬀerent and representative binding modes
by docking (Fig. S7†), all of them preserving the p–p stacking
interaction with Phe398 observed for TDP. Nevertheless, the
hydroxyethylene tail seems to be rather exible and adopts
diﬀerent orientations in the three poses, being involved in
hydrogen bonds with various amino acids (His82, His51 or His
304). We had observed before for another protein system that
diﬀerent binding modes of one ligand directly contribute to the
spin diﬀusion and the NMR signals represent an average of
them.12 In order to better understand the binding behaviour of
17, we used all three representative binding poses as a starting
point of an MD simulation for 1 ns (Fig. S13†). It is remarkable
that only one pose maintains its binding mode during the MD
simulation (Fig. S7,† docked pose 2), conrming that this pose
corresponds to the binding mode of 17 to D. radiodurans DXS in
solution (Fig. 2b). The best-scoring bindingmodes for 17 and 15
based on their RSTI are shown in Fig. 2b. It is noteworthy that for
ligand 15 the best scoring RSTI (0.52) binding mode (Fig. S11,†
docked pose 1) is very similar to the modelled one (Fig. 1b). In
the other plausible binding mode proposed by the docking
studies, 15 binds in the diphosphate pocket of TDP (Fig. S7,†
docked pose 2) but displays negative RSTD and RINPHARMA values.
The STI methodology was therefore able to clearly diﬀerentiate
between both binding modes and allowed us to validate theThis journal is © The Royal Society of Chemistry 2014modelled binding mode of 15. In the case of 16, we could only
record STD and trNOE data. Docking identied two represen-
tative binding modes of 16 in the TDP-binding pocket of D.
radioduransDXS, which are shown in Fig. 3 (Fig. S12, Table S1†).
The absence of INPHARMA peaks could be explained by the
small overlap between 16 and 17 in both poses. Owing to the
lack of hydrogen-bonding interactions and the inherently ex-
ible ethylene linker, the imidazolyl moiety presumably adopts
various conformational states. MD simulations for 1 ns of the
two selected representative poses further conrm this
assumption. In fact, although the two poses are maintained
during the simulation period, we observed several rotations of
the imidazolyl moiety. The high degree of exibility combined
with the small overlapping area with 17 are putatively the
reasons why we only observed weak trNOE and no INPHARMA
peaks. Regarding the RST values, one of the two poses (Fig. S11,†
docked pose 2, RST ¼ 0.45) seems to be slightly preferred overChem. Sci., 2014, 5, 3543–3551 | 3547
Table 2 Experimental IC50, calculated Ki values and ligand eﬃciencies
(LEs) of synthesised derivatives of fragment 15. LEs are derived from






1200  200d 310  65 0.27
>2000e — —
595  81 151  22 0.24
Fig. 3 The two representative docked poses of 16 in the TDP-binding
pocket of D. radiodurans DXS. The validated binding mode of deaza-
thiamine (17) is also shown. Deazathiamine (17) skeleton: C: magenta.
Inhibitor 16 skeleton: C: blue or C: light blue.












































View Article Onlinethe other (Fig. S12,† docked pose 1, RST ¼ 0.42). Given that the
validation of the binding mode within D. radiodurans DXS was
possible just for 15 and given that 15 and 16 are equally
amenable to follow-up synthesis, we focused our attention on
the growing and optimisation of fragment 15.a IC50 and calculated Ki values were determined using a photometric
assay using the programme Dynat.31 Full details of the biochemical
assay conditions and the calculation of the Ki values are provided in
the ESI. b Values indicate the experimentally derived ligand eﬃciency
(LE) calculated as DG/N, where DG corresponds to the Gibbs free
binding energy (kcal mol1) calculated as DG ¼ RT ln K0/Ki, Ki being
the calculated inhibition constant. N corresponds to the number of
non-hydrogen atoms of that specic molecule. c 20% inhibition at
2000 mM. d Compound 21 has been tested as a mixture of 4- and 5-
substituted regioisomers (21a + 21b). e 40% inhibition at 2000 mM.Fragment growing and optimisation
To do so, we modelled and synthesised the compounds shown
in Table 2 (Fig. S14, Scheme S1–S6†). The synthesis involves in
every case a late-stage introduction of the moiety targeting the
thiazolium and diphosphate pockets in an SN2 reaction. Frag-
ment 19 constitutes a regioisomer of 15 and we designed it so as
to gain a hydrogen-bonding interaction with the side chain of
Glu373, provided that the carboxylic acid is present in its
protonated form. To circumvent the uncertainty related to the
protonation state of the side chain of Glu373, we designed
compound 20. According to the modelled pose, the amino
group of 20 should form two strong hydrogen bonds with the
side chain of Glu373 – whether protonated or not – as well as
with the backbone C]O of Pro347. For both fragments, all the
other interactions of the original fragment 15 are preserved. As
shown in Table 2, we observed only 20% and 0% inhibition at 2
mM for 19 and 20, respectively. Addressing the side chain of
Glu373 seems therefore unreliable in terms of molecular
recognition and addressing other amino-acid residues in the
TDP-binding site of DXS would appear to be a better strategy for
SBD.
To grow the fragment towards the diphosphate-binding
pocket, we designed and tested 21 as a mixture of two
regioisomers (21a and 21b), which displays an IC50 value of 1.2
 0.2 mM. A possible explanation of the higher inhibitory
potency of 21 with respect to 20 could be the capability of the
aminoethylene linker to anchor 21 in a slightly diﬀerent
orientation with respect to 20, which might help the binding3548 | Chem. Sci., 2014, 5, 3543–3551event to occur. This favourable anchoring both on the le- and
right-hand sides of the molecule is probably responsible for the
gain in potency. We accessed 22 conveniently in one step,
starting from imidazole and the corresponding commercially
available bromide. In the modelled pose, the p-stacking inter-
action with Phe398 is preserved as well as the two hydrogen
bonds of 15. Moreover, the triuoromethyl group is involved in
numerous lipophilic interactions with the side chains of
Phe398, His124 and Ile371. It is also engaged in an electrostatic
interaction with the positively charged guanidinium side chain
of Arg401. The inhibitory potency of 22 (40% inhibition at 2 mM)
can be considered comparable to that of 15 but its optimisation
is more straightforward owing to the reduced number of
synthetic steps. In addition, a benzene ring has more free
substitution points compared to a pyridine ring. To increase the
lipophilic contacts of 22, we expanded the imidazolyl ring into a
benzimidazolyl moiety, leading to compound 23, whichThis journal is © The Royal Society of Chemistry 2014
Fig. 4 (a) NOESY spectrum of inhibitors 23 and 17 in the presence of DXS clearly shows trNOE (black) and INPHARMA (green) peaks. Peak
assignment is indicated on the axes for 23 (red) and 17 (purple). (b) Validated binding mode for 23 in the TDP-binding pocket of D. radiodurans
DXS. Colour code: inhibitor 23 skeleton: C: orange.












































View Article Onlineinteracts, according to our modelling, with Val80, His82 and
Ile187. As a result, 23 (IC50 ¼ 595  81 mM) is three times more
potent than the original fragment 15. The inhibitory potency of
23 is in the same range as that of the non-selective thiamine
analogue deazathiamine (17; IC50¼ 430 68 mM), making 23 an
attractive and novel thiamine analogue. The fact that this
fragment was designed de novo could facilitate and enable
subsequent tuning of the selectivity over human thiamine- or
TDP-binding targets.
We validated the binding mode of 23, using the STI method.
Firstly, we recorded an STD spectrum of 23, which showed STD
enhancement only in the presence of DXS, conrming the
binding event (Fig. S15†). We observed the same in a trNOE
spectrum (Fig. 4a). In the subsequent NOESY spectrum of 23
and deazathiamine (17) we clearly observed INPHARMA peaks
(Fig. 4a), conrming that both compounds bind in the same
pocket. As described above for 15, we generated three repre-
sentative poses for 23 (Fig. S16, Table S1†). The docked pose of
23 displaying the best RSTI score (RSTI¼ 0.57) is shown in Fig. 4b
(Fig. S16,† docked pose 3). Two other plausible docking modes
show binding of 23 in the diphosphate pocket (Fig. S16,†
docked pose 1, RSTI ¼ 0.4) and the histidine-rich pocket
(Fig. S16,† docked pose 2, RSTI ¼ 0.46), both having lower DG
values than the pose shown in Fig. 4b, according to HYDE
scoring (Table S1†).
In the best pose according to the NMR studies (Fig. 4b), the
le-hand side of 23 maintains the same interactions with DXS
with respect to the originally modelled pose, while the benzi-
midazolyl ring points into the histidine-rich pocket rather than
towards the diphosphate pocket as is the case for the modelled
pose of 23. We did not observe the modelled pose of 23 amongst
the 30 docked poses but it was included in the evaluation and,
not surprisingly, received a lower RSTI score (RSTI ¼ 0.29): this
fact further validates the pose shown in Fig. 4b for 23.This journal is © The Royal Society of Chemistry 2014Taking advantage of the NMR studies, applied here for the
rst time, we were able to investigate the binding mode of 23,
setting the stage for further fragment-growing and optimisation
to aﬀord lead-like compounds with improved inhibitory
potency, even in the case of a very complicate binding behav-
iour. It is worthwhile to underline that the binding pose vali-
dated with the STI approach taken here, diﬀers from the pose
obtained purely by modelling and that the structure-based
fragment optimisation of 23 based on the modelled pose alone
would have led to fragment growing in the wrong direction. This
observation conrms that the validation of the binding mode of
the fragments in the rst steps of the fragment-to-lead process
is fundamental to render the whole process more eﬃcient and
less time- and material-consuming.Conclusions
In conclusion, we have successfully applied the innovative
NMR-based STI methodology for the rst time to a SBD project.
In our de novo FBD of inhibitors of D. radiodurans DXS, the STI
methodology was essential to validate the binding mode of the
rst promising fragment (15, IC50 ¼ 1.8  0.5 mM) and enabled
us to focus our eﬀorts on just one fragment and perform further
fragment-growing and optimisation leading to 23. Compound
23 is three times more potent than 15 (IC50 ¼ 595  81 mM) and
about as potent as deazathiamine (17), making 23 an attractive
thiamine analogue with the potential for better selectivity over
other thiamine- or TDP-dependent enzymes, which will have to
be realised in future cycles of optimisation. We investigated the
binding mode of 23 using STI and found it to be diﬀerent from
the one modelled in the absence of experimental data. Our
ndings show that the STI approach represents an attractive
alternative to protein X-ray crystallography enabling SBD and
FBD projects on targets for which a reliable crystallographicChem. Sci., 2014, 5, 3543–3551 | 3549












































View Article Onlineprotocol is not available. A further advantage is that the binding
mode in solution is derived. The STI methodology therefore
holds the potential to nd application in a wide range of
medicinal-chemistry or chemical-biology projects.Acknowledgements
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